Introgen Therapeutics Inc. said its sublicense to the mda-7 gene covers all gene therapy indications. A story in the Aug. 28, 2001, issue of BioWorld Today quoted a company collaborator as mistakenly saying pancreatic cancer was excluded.

Editor¿s note: The change has been made in BioWorld Online.